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Abstract
Introduction Atypical antipsychotics have significantly im-
proved the quality of life for schizophrenic patients. Despite
their beneficial effects, these antipsychotics induce weight
gain, diabetes, and dyslipidemia. The aims of this study were
to investigate the antioxidative activity of paraoxonase and
assess lipid profile as a cardiovascular risk factor in patients
with schizophrenia under long-term clozapine or risperidone
treatment.
Methods The study included 66 patients with schizophrenia
under clozapine or risperidone treatment and 19 healthy con-
trol subjects. Serum paraoxonase activities against paraoxon
(PON(PO)), phenylacetate (PON(PA)), dihydrocoumarin
(PON(DHC)), serum Trolox equivalent antioxidant activity
(TEAC), antioxidant gap (GAP), and lipid profile were
determined.
Results PON(DHC) activity was reduced in both antipsychot-
ic drug-treated groups (clozapine 43.46±1.06 U/ml, p<0.001;
risperidone 50.57±1.54U/ml, p<0.01; control 52.27±1.34 U/
ml). A similar pattern was observed for the PON(DHC)/HDL-
cholesterol (HDLC) ratio. On the contrary, PON(PO) and
PON(PA) were increased in the treated group, but the corre-
sponding paraoxonase/HDLC ratios were not significantly
different from controls, except for PON/HDLC in the cloza-
pine group. TEAC and GAP were only decreased in the
clozapine-treated group.
Conclusions In patients with schizophrenia, clozapine or ris-
peridone treatment had different effects on various paraoxo-
nase activities. The results of the present study suggest that
patients with schizophrenia might be at increased risk for
metabolic and cardiovascular disease related to reduced
PON(DHC), TEAC, and GAP.




PON(PO) Paraoxonase’s activity against paraoxon
PON(DHC) Paraoxonase’s activity against
dihydrocoumarin
PON(PA) Paraoxonase’s activity against phenylacetate
HDLC HDL-cholesterol
TEAC Trolox equivalent antioxidant activity
GAP Antioxidant gap
Introduction
Atypical antipsychotics introduced after 1990 have signifi-
cantly reduced the frequency of acute extrapyramidal symp-
toms and improved the quality of life for patients with
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schizophrenia. Unfortunately, substantial weight gain, glucose
dysregulation, and hyperlipidemia induced by these drugs are
important concerns for many individuals because these ad-
verse effects are more common and severe with atypical
antipsychotics than with conventional ones (Allison et al.
1999a; Ruetsch et al. 2005). Moreover, levels of mortality
from obesity-related conditions, such as coronary heart dis-
ease, are higher in patients with schizophrenia (Allison et al.
2009).
Among the atypical antipsychotics agents, clozapine and
olanzapine appear to have the greatest potential to induce
weight gain, diabetes, and dsylipidemia, while risperidone
has an intermediate effect (Allison et al. 1999b; Baptista
et al. 2008).
Paraoxonases are relatively newly identified antioxidant
enzymes that are synthesized by the liver and transported
almost exclusively on high-density lipoprotein (HDL). Para-
oxonase 1 (PON1) has been the focus of recent cardiovascular
research because of its evident capacities to protect low-
density lipoproteins (LDLs) against oxidative stress and pre-
vent atherogenesis (Precourt et al. 2011). These protective
functions of PON1 may be related to its ability to hydrolyze
oxidized lipids on LDL and to prevent the accumulation of
oxidized LDL, which is believed to be central to the initiation
and progression of atherosclerosis (Mackness et al. 2003).
Previous studies have shown that individuals with low PON
activity, regardless of genotype, are at greater risk for devel-
oping cardiovascular disease (CAD) (Durrington et al. 2001;
Mackness et al. 2001; Jarvik et al. 2000). Nevertheless, the
influence of atypical antipsychotic drugs on PON activity and
its relationship with metabolic and cardiovascular risk factors
in psychiatric patients remain to be fully elucidated. Only two
studies, having partially contradictory results, have evaluated
the impact of atypical antipsychotic drugs on PON activity.
The first study found no significant difference between PON
activity levels in female patients receiving antipsychotics and
those in controls (Ozenoglu et al. 2008). Despite this, PON
was positively correlated with body mass index (BMI), and
the PON1/HDL ratio was positively correlated with triglycer-
ide levels in subjects under treatment, but not in controls. The
second study found reduced serum PON1 activity in patients
with schizophrenia treated with olanzapine but not quetiapine,
when compared with controls, while serum levels of total
cholesterol and LDL-C in the olanzapine group were signifi-
cantly higher than those of quetiapine and control groups
(Ünsal et al. 2013). These results, although partially contra-
dictory, suggest a potential contribution of paraoxonase level
and/or activity changes in atypical antipsychotic drug-induced
cardiovascular risk. Nevertheless, the impact of atypical anti-
psychotic drugs on atherogenesis remains unclear. Several
studies have shown that long-term treatment with atypical
antipsychotics may induce an oxidant/antioxidant imbalance
and increase lipid peroxidation (Fehsel et al. 2005; Gama et al.
2006; Zhang et al. 2006). Levels of superoxide dismutase
(SOD) were significantly increased in patients with schizo-
phrenia (Zhang et al. 2006, 2012), but risperidone treatment
reduced elevated blood SOD levels in schizophrenic subjects
(Zhang et al. 2012). Clozapine-induced protein oxidation has
been suggested as a possible mechanism of antipsychotic-
associated metabolic alterations (Baig et al. 2010; Walss-
Bass et al. 2008).
The purpose of our study was therefore to investigate the
impact of long-term atypical antipsychotic treatment with
clozapine and risperidone on cardiovascular risk and antioxi-
dant protection markers, including serum paraoxonase activ-
ities against paraoxon (both basal and NaCl-stimulated PON
activity), phenylacetate (arylesterase PON activity), and
dihydrocoumarin (lactonase PON activity). Because lactonase
PON activity is hypothesized to be responsible for the antiox-
idant capacity of HDL (Gaidukov and Tawfik 2007), we also




The present study was an observational study with cross-
sectional design. The subjects were selected from outpatients
treated at a psychiatric hospital in Sapoca, Buzău, Romania,
between December 2010 and June 2011. A senior psychiatrist
identified patients who met the following criteria: (1) fit the
Diagnostic and Statistical Manual of Mental Disorders IV
(DSM-IV) criteria of schizophrenia (First and Pincus 1999),
(2) a minimum of 3 years’ duration of disease, and (3) a 1-year
minimum duration of antipsychotic treatment with clozapine
or risperidone; these subjects were asked to participate in the
study. All patients were evaluated with the ItemGroup Check-
list section of the Schedules for Clinical Assessment in Neu-
ropsychiatry (SCAN) in order to confirm the diagnosis (Wing
et al. 1990). The exclusion criteria were the presence of acute
or chronic illnesses known to affect the immune, endocrine, or
metabolic systems, and any additional chronic medications.
The study was approved by the local ethics committee and
conducted according to the ethical obligations of the Declara-
tion of Helsinki. From the initial sample of 70 patients, 4 were
excluded for physical reasons (3 patients with acquired im-
mune deficiency syndrome [AIDS] and 1 with hepatitis C),
leaving 66 patients (44 under clozapine treatment [10 females
and 34 males; 27 nonsmokers and 15 smokers], and 22 under
risperidone treatment [7 females and 15 males; 15 non-
smokers and 5 smokers]) who were entered into the study.
We have selected clozapine and risperidone for our study,
since these two drugs are already known among the atypical
antipsychotic drugs as potent (clozapine) or intermediate
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(risperidone) inducers of lipid metabolism alterations (Allison
et al. 1999b; Baptista et al. 2008). Taking into account their
proved dyslipidemic potential, we intended to compare also
their strength in terms of the oxidative capacity. We also
enrolled 19 healthy subjects (12 females and 7 males; 9
nonsmokers and 5 smokers) without current or past psychiat-
ric disorders as controls, using the same exclusion criterion
described above. Neither patients nor controls had alimentary
restrictions, and no vegetarian or vegan subjects were includ-
ed in the study. There was no statistical trend difference
among the groups, in terms of smoker/nonsmoker distribution
(chi-square test). After a complete description of the study, all
patients and healthy controls provided informed consent to
participate in the investigation. All of the subjects in both
groups were of European Caucasian origin.
The average durations of illness were 11.4±5.6 and 9.4±
4.7 years, and treatment durations were was 5.8±4.7 and 6.1±
5.4 years in the clozapine and risperidone groups, respective-
ly. Clozapine dosages ranged from 100 to 450 mg daily
throughout the treatment period, while risperidone dosing
ranged from 2 to 6 mg daily. None of the subjects experienced
agranulocytosis during the study period.
Sample processing
All subjects underwent blood sampling (10 ml) into heparin-
containing tubes after an overnight fast. After centrifugation,
the plasma was retained on ice for PON activity and TEAC
assays. Reagents and ultrapure water were treated with Chelex
100 (Merck, Darmstadt, Germany) to bind transitional metals.
All reagents were of pure analytical quality and were pur-
chased from Sigma-Aldrich Chemie (Steinheim, Germany),
unless otherwise indicated. All assays were carried out on
duplicate samples on a Perkin-Elmer Lambda EZ 210 UV–
VIS spectrophotometer (Perkin-Elmer Inc., Boston, MA,
USA) or on a Cobas Mira Plus automatic analyzer (Roche
Diagnostics, Basel, Switzerland). Serum PON enzymatic ac-
tivity was spectrophotometrically determined using three dif-
ferent substrates.
PON activity against paraoxon (PON(PO))
To measure paraoxonase activity, serum was incubated in
Tris–HCl buffer (100 mmol/l, pH 8.0) containing
5.5 mmol/l paraoxon (O,O-diethyl O-p-nitrophenyl phos-
phate, Sigma-Aldrich Chemie) and 2 mmol/l CaCl2 either
with 1 mol/l NaCl (salt-stimulated activity: PON(PO-
NaCl)) or without NaCl (basal activity: PON(PO)). The
generation rate of the product, p-nitrophenol, was moni-
tored at 412 nm. Enzyme activity was calculated from its
molar extinction coefficient 18,290 M−1 cm−1. One unit of
PON is defined as 1 nmol p-nitrophenol/ml/min under the
above-described assay conditions (Richter et al. 2004).
Arylesterase PON activity (PON(PA))
To measure arylesterase activity, serum was added to Tris–
HCl buffer (100 mmol/l, pH 8.0) containing 2 mmol/l CaCl2
and 2 mmol/l phenylacetate (acetic acid phenyl ester 99 %;
Sigma-Aldrich Chemie). The rate of phenylacetate hydrolysis
was monitored at 270 nm. After subtracting the nonenzymatic
hydrolysis, enzyme activity was calculated from the molar
extinction coefficient of the product, 1.310 M−1 cm−1. One
unit of PON(PA) activity is defined as 1 μmol of p--
nitrophenol/ml/min under the above-described assay condi-
tions (Haagen and Brock 1992; Kawai et al. 1990).
Lactonase PON activity (PON(DHC))
Lac t ona s e PON ac t i v i t y was mea su r ed u s i ng
dihydrocoumarin (DHC) as substrate. Briefly, serum and sub-
strate were added in the buffer, and the absorbance was
monitored at 270 nm. Activities are expressed as units per
milliliter (Gaidukov and Tawfik 2007).
Plasma total antioxidant activity (TEAC)
Plasma total antioxidant activity was determined based on the
6-hydroxy-2,5,7,8-tetramethylchroman-2 carboxylic acid
(Trolox) equivalent antioxidant capacity assay developed by
Miller et al. with modifications (Miller and Rice-Evans 1996;
Re et al. 1999). The TEAC assay measures the relative abil-
ities of antioxidants to scavenge the 2,2′-azino-bis (3-ethyl-
benzothiazoline-6-sulfonic acid) (ABTS) radical cation
(ABTS*+) compared with the antioxidant potency of standard
amounts of Trolox, the water-soluble vitamin E analog. The
ABTS radical was generated from the interaction between
ABTS and potassium persulfate. Solution containing ABTS*+
was added to the serum samples, and the absorbance was read
after 1 min at 734 nm and compared to that of 5 mM phos-
phate buffer. We calculated the percentage inhibition of the
absorbance, which is directly proportional to the antioxidant
activity of the sample. The assay was calibrated against a
calibration curve with Trolox as the standard, and the results
are expressed as millimoles per liter of Trolox.
Plasma residual antioxidant activity (“antioxidant gap”; GAP)
The principal antioxidants (by mass and activity) of human
plasma are albumin and uric acid, which account for 51–57 %
of the total antioxidant activity (Miller and Rice-Evans 1996;
Miller et al. 1997). Antioxidant gap reflects the combined
activity of other extracellular antioxidants and was calculated
by subtracting the antioxidant activity ascribable to albumin
and uric acid from the TEAC value for each sample according
to the formula: GAP = TEAC − [(Albumin × 0.69) + uric
acid], where 0.69 is the TEAC value for human serum
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albumin, while 1.0 is the TEAC value for serum uric acid;
albumin = serum albumin concentration (expressed as
mmol/L); uric acid = serum uric acid concentration (expressed
as mmol/L). The results were expressed as millimoles per liter
of Trolox activity.
Routine biochemical analyses
We quantified total cholesterol (TC), triglyceride (TG), HDL-
cholesterol (HDLC), albumin, and uric acid levels using com-
mercially available kits from DiaSys (Holzheim, Germany).
Statistical analysis
All data are presented as adjusted predictive values based on a
linear regression model using age and BMI as independent
variables. No data imputations were performed. The data were
therefore corrected for age and BMI as potential confounders.
Data analysis was performed using GraphPad InStat software
package (GraphPad Software, Inc., La Jolla, CA, USA). Dif-
ferences between groups were computed using analysis of
variance (ANOVA) with parametric (Tukey’s) or nonparamet-
ric (Kruskal–Wallis) post hoc tests. The strength of association
between pairs of variables was assessed by Pearson’s correla-
tion coefficient. A p value <0.05 was considered statistically
significant.
Results
A total of 44 clozapine-treated and 22 risperidone-treated
patients were enrolled in the study. All patients fulfilled the
DSM-IV criteria for schizophrenia. The participants’ demo-
graphic and clinical characteristics are shown in Table 1.
Clozapine-treated patients had significantly lower age
(p<0.001) and higher BMI (p<0.05), TG (p<0.001), CT
(p<0.001), and HDLC values (p<0.001) than control sub-
jects, while risperidone-treated subjects were younger
(p<0.001) but did not differ from the control group with
regard to BMI, TG, or CT (Table 1). The two groups of
schizophrenic patients also differed significantly in all these
characteristics (Table 1).
Data regarding oxidative stress-related parameters are
shown in Figs. 1, 2, and 3. Paraoxonase activities against
paraoxon as substrate (either basal or stimulated activity) were
significantly higher in both groups of patients with schizo-
phrenia than in control subjects (Fig. 1). The same variation
was observed for PON(PA) (Fig. 2). Conversely, PON(DHC)
was significantly lower in the two groups of patients than in
the controls (Fig. 2).
Plasma HDLC concentrations were significantly higher in
both groups of patients than in control subjects (Table 1). To
assess whether altered paraoxonase activity was due to a
change in HDL level or to a stabilizing effect of HDL on
paraoxonase, we calculated paraoxonase/HDLC ratios
(Table 2).
We found that the PON(DHC)/HDLC ratio was signifi-
cantly lower in the clozapine (p<0.001) and risperidone
(p<0.01) groups than controls. The variation was significantly
higher in the clozapine group (p<0.001) than in the risperi-
done group. Moreover, while PON(PO) activity increased
after treatment with both atypical antipsychotic drugs, the
PON(PO)/HDLC ratio was significantly decreased in the clo-
zapine group (p<0.01). Although there was no difference
between the risperidone and control groups in terms of the
PON(PO)/HDLC ratio, there was a significant difference be-
tween the clozapine and risperidone groups (p<0.01).
PON(PO-NaCl)/HDLC and PON(PA)/HDLCwere not signif-
icantly different among the three groups. TEAC and GAP

















Age (years) 38.47 (1.50) 47.47 (3.19) 62.31 (11.67) <0.001 <0.001 <0.05
BMI (kg/m2) 27.145 (0.82) 23.71 (0.59) 23.59 (1.88) <0.05 n.s. <0.05
TGa (mg/dl) 182.64 (14.36) 140.47 (3.05) 140.47 (3.05) <0.001 n.s. <0.05
CTb (mg/dl) 275.82 (11.35) 237.47 (1.67) 230.82 (2.26) <0.001 n.s. <0.05
HDLCc (mg/dl) 48.20 (2.64) 41.30 (0.87) 37.168 (0.54) <0.001 <0.01 <0.001
Albumin (mg/dl) 5.80 (0.13) 5.81 (0.21) 5.17 (0.06) <0.05 <0.05 n.s.
Acid uric (mg/dl) 5.14 (0.42) 4.64 (0.51) 4.92 (0.23) n.s. n.s. n.s.
All the values are expressed as mean (SEM)
a For TG, N=43 for the clozapine group, N=21 for the risperidone group, and N=15 for the control group
b For CT, N=43 for the clozapine group, N=22 for the risperidone group, and N=16 for the control subjects
c For HDLC, N=43 for the clozapine group, N=21 for risperidone group, and N=17 for the control subjects
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were significantly lower in the clozapine group than in the
control group (both p<0.001, Fig. 3).
Although there was no difference between the risperidone
and control groups in terms of TEAC or GAP, there was a
significant difference between the clozapine and risperidone
groups (p<0.01 and p<0.05, respectively). We also found that
PON(DHC) was positively correlated with TEAC and GAP in
all three groups (clozapine: TEAC r=0.478, p<0.01, GAP r=
0.775, p<0.0001; risperidone: TEAC r=0.927, p<0.0001,
GAP r=0.985, p<0.0001; control: TEAC r=0.973,
p<0.0001, GAP r=0.994, p<0.0001). We found no sex-
associated differences in any of the oxidative stress-related
parameters, either in schizophrenia or control groups.
Discussion
An increasing amount of evidence suggests a possible in-
crease in cardiovascular events in patients with schizophrenia
treated with atypical antipsychotic drugs, and this is hypoth-
esized to be secondary to lipid (Allison et al. 1999a, b, 2009;
Ruetsch et al. 2005), as well as to glucose metabolism
dysregulation (Henderson et al. 2005; Zhang et al. 2014).
Serum paraoxonase is a HDL-associated hydrolase with a
broad range of substrates (paraoxon, phenylacetate,
dihydrocoumarin) and inhibits LDL oxidation. Previous stud-
ies have shown that paraoxonase activity towards paraoxon is
inversely related to the level of CAD and represents a predic-
tive risk factor for subsequent coronary events independent of
all other established risk factors, with the exception of HDL
(Ayub et al. 1999; Mackness et al. 2003). The significant
decreases in PON(DHC) activities in clozapine- and
risperidone-treated patients in the present study support the
hypothesis of high cardiovascular risk associated with chronic
atypical antipsychotic drug administration. Although we
found increased activities of PON(PO) and PON(PA), it is
important to emphasize that lactonase activity is the endoge-
nous activity of paraoxonase and directly mediates its anti-
atherogenic functions. Whereas traditional paraoxonase and
arylesterase assays weakly reflect paraoxonase-HDL complex
levels, lactonase activity correlates significantly better with
the degree of paraoxonase binding to HDL and may thus
provide a better indication of the antioxidant and anti-
atherogenic capacities of the HDL particles on which the
Fig. 1 PON(PO) and PON(PO-NaCl) values in clozapine- and risperidone-treated schizophrenic patients vs. the control group
Fig. 2 PON(PA) and PON(DHC) values in clozapine- and risperidone-treated schizophrenic patients vs. the control group
Psychopharmacology (2014) 231:4703–4710 4707
enzyme is anchored (Gaidukov and Tawfik 2007). Therefore,
we also calculated the paraoxonase/HDLC ratios (see
Table 2).
Surprisingly, PON/HDLC was significantly lower in the
clozapine group than in either the control group (p<0.001) or
the risperidone group (p<0.01). It is already established that a
decreased paraoxonase/HDL ratio may lead to a reduction in
the antioxidant capacity of HDL, which might contribute to
the accelerated development of atherosclerosis (Paragh et al.
1999). Thus, our results suggest that paraoxonase/HDL may
be a better predictor of atherosclerosis in patients with schizo-
phrenia treated with clozapine or risperidone than plasma
HDLC concentrations or paraoxonase activity. The present
study also demonstrates that HDLC increases in patients with
schizophrenia who are treated with atypical antipsychotic
drugs, suggesting that HDLC may not be a strict requirement
for antioxidant or even cardiovascular protection. Also
another study showed that the cardiovascular predictive
value of PON1 activity is higher than that of HDLC
(Navab et al. 1997).
In accordance with our results, a recent study reported that
the clinical significance of HDLC concentrations in the gen-
eral population is markedly heterogeneous: high
concentrations do not necessarily lower the cardiometabolic
risk, putting the beneficial role of HDLC in doubt (Voight
et al. 2012).
Although few previous in vitro or animal studies have
shown antioxidant properties and the oxidative stress modu-
latory potential of clozapine (Dalla Libera et al. 1998; Pillai
et al. 2007), we found that this atypical antipsychotic drug
reduced TEAC and GAP, suggesting that it has a negative
impact on serum antioxidant protection in human subjects. To
our knowledge, this is the first study to evaluate the impact of
long-term clozapine and risperidone treatment on TEAC and
GAP in human subjects with schizophrenia.
Decreased PON(DHC) activity in our study might be
responsible for the observed reduction in TEAC and GAP.
Although clozapine showed lower levels of oxidative
stress (measured as plasma malondialdehyde) than risper-
idone after 3 weeks of treatment in a previous study
(Stefan Kropp et al. 2005), our results suggest that long-
term clozapine treatment has a stronger negative impact
than risperidone on the plasma antioxidant protection and
on the anti-atherogenic capacity of the HDL particles.
This pattern also recalls the dyslipidemic potency pattern
of these drugs (Allison et al. 1999b; Baptista et al. 2008).
Fig. 3 TEAC and GAP values in clozapine- and risperidone-treated schizophrenic patients vs. the control group














































All the values are expressed as mean (SEM)
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In conclusion, clozapine or risperidone treatment of pa-
tients with schizophrenia affects various paraoxonase activi-
ties, reducing PON(DHC) and increasing PON, PON(NaCl),
and PON(PA). The decrease in PON(DHC) activity was con-
comitant with a paradoxical increase in HDLC in our subjects
with schizophrenia. Based on our results, we suggest that the
paraoxonase/HDLC ratio may be a better candidate for a
cardiovascular risk marker than HDLC or paraoxonase activ-
ity alone.
The influence of clozapine on all the measured parameters
was stronger than that of risperidone, showing that it could
have a stronger negative impact on cardiovascular risk. The
results of the present study also suggest that patients with
schizophrenia might be at increased risk for metabolic and
cardiovascular disease related to reduced PON(DHC), TEAC,
and GAP.
We found no sex influence on the levels of all the measured
parameters. The topic of gender differences in antioxidant
status is complex, not sufficiently studied, and sometimes
controversial. There are studies that found no gender differ-
ences (e.g., TEAC) (Rahman et al. 2000), while others report-
ed such sex dependence of various parameters (e.g., TEAC,
PON) (Valabhji et al. 2001; Winnier et al. 2007).
Because paraoxonase and plasma antioxidants can be mod-
ulated by diet (Esfahani et al. 2011; Koncsos et al. 2011;
Rantala et al. 2002), our results indicate that patients with
schizophrenia under long-term clozapine and risperidone
treatment might benefit from dietary interventions. However,
further prospective studies will be requested to test this hy-
pothesis. We also suggest that patients who receive clozapine
or risperidone treatment should be followed up more carefully
in terms of cardiovascular risk.
There are a number of limitations to this study. The patient
sample included individuals with schizophrenia under chronic
(longer than 1 year) atypical antipsychotic drug treatment. The
results may not be generalizable to patients with shorter treat-
ment, other psychotic disorders, or those receiving antipsy-
chotic medication for other illnesses. Due to the cross-
sectional design of the study, it is difficult to make causal
inference. Also the results should be interpreted with caution,
since they may differ when another time frame would be
chosen. Future prospective studies should confirm our
conclusions.
The significant differences in BMI and age between the
groups represent other limitations, despite the fact that they
were considered confounding factors and regression analysis
was used. Another limitation is that several aspects (e.g.,
exercise habits) known to influence oxidative parameters were
not evaluated.
This study only dealt with two atypical antipsychotic med-
ications. Further research is required to determine how the
findings of this study are relevant to treatment with other
antipsychotic medications, and the results presented here
should be interpreted with caution. Although our study had a
limited sample size, this could be advantageous in that it is
more likely to have biased the results toward a negative
finding because of insufficient statistical power.
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